1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Healthpoint Biotherapeutics – Product Pipeline Review – 2013

Healthpoint Biotherapeutics – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 39 pages

Healthpoint Biotherapeutics – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Healthpoint Biotherapeutics - Product Pipeline Review - 2013” provides data on the Healthpoint Biotherapeutics’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Healthpoint Biotherapeutics’s corporate website, SEC filings, investor presentations and featured press releases, both from Healthpoint Biotherapeutics and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Healthpoint Biotherapeutics - Brief Healthpoint Biotherapeutics overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Healthpoint Biotherapeutics human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Healthpoint Biotherapeutics with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Healthpoint Biotherapeutics’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Healthpoint Biotherapeutics’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Healthpoint Biotherapeutics in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Healthpoint Biotherapeutics’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Healthpoint Biotherapeutics.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Healthpoint Biotherapeutics and identify potential opportunities in those areas.

Table Of Contents

Healthpoint Biotherapeutics - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Healthpoint Biotherapeutics Snapshot 5
Healthpoint Biotherapeutics Overview 5
Key Information 5
Key Facts 5
Healthpoint Biotherapeutics - Research and Development Overview 6
Key Therapeutic Areas 6
Healthpoint Biotherapeutics - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Healthpoint Biotherapeutics - Pipeline Products Glance 10
Healthpoint Biotherapeutics - Late Stage Pipeline 10
Phase III Products/Combination Treatment Modalities 10
Healthpoint Biotherapeutics Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Healthpoint Biotherapeutics - Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Healthpoint Biotherapeutics - Drug Profiles 13
Drug For Debridement 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Drug For Venous Statis Ulcer 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
HP802-247 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Healthpoint Biotherapeutics - Pipeline Products by Route of Administration 16
Healthpoint Biotherapeutics - Recent Pipeline Updates 17
Healthpoint Biotherapeutics - Dormant Projects 20
Healthpoint Biotherapeutics - Discontinued Pipeline Products 21
Discontinued Pipeline Product Profiles 21
ICX-PRO 21
Healthpoint Biotherapeutics - Company Statement 22
Healthpoint Biotherapeutics - Locations And Subsidiaries 24
Head Office 24
Healthpoint Biotherapeutics, Recent Developments 25
Healthpoint Biotherapeutics- Press Release 25
Dec 08, 2010: DPT Receives FDA Approval To Commercially Manufacture Collagenase SANTYL Sterile Ointment 25
Aug 10, 2010: Healthpoint Initiates Randomized Study To Evaluate Effectiveness Of Collagenase SANTYL Ointment In Healing Of Diabetic Foot Ulcers 25
Jan 26, 2010: HEALTHPOINT Launches Collagenase SANTYL Ointment In Canada 26
Financial Deals Landscape 28
Healthpoint Biotherapeutics, Deals Summary 28
Healthpoint Biotherapeutics, Pharmaceuticals and Healthcare, Deal Details 29
Asset Transactions 29
Healthpoint Biotherapeutics Acquires Regranex Gel From Systagenix 29
Healthpoint Acquires Two Cell Based Technologies From Intercytex 31
Partnerships 33
Healthpoint Enters Into Agreement With Hydrofera 33
Licensing Agreements 34
CareFusion Enters Into Licensing Agreement With Healthpoint 34
Acquisition 36
Smith and Nephew Completes Acquisition Of Healthpoint Biotherapeutics, Wound Care Company, For $782 Million 36
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39



List of Tables

Healthpoint Biotherapeutics, Key Information 5
Healthpoint Biotherapeutics, Key Facts 5
Healthpoint Biotherapeutics - Pipeline by Indication, 2013 7
Healthpoint Biotherapeutics - Pipeline by Stage of Development, 2013 8
Healthpoint Biotherapeutics - Monotherapy Products in Pipeline, 2013 9
Healthpoint Biotherapeutics - Phase III, 2013 10
Healthpoint Biotherapeutics - Phase II, 2013 11
Healthpoint Biotherapeutics - Pre-Clinical, 2013 12
Healthpoint Biotherapeutics - Pipeline By Route of Administration, 2013 16
Healthpoint Biotherapeutics - Recent Pipeline Updates, 2013 17
Healthpoint Biotherapeutics - Dormant Developmental Projects,2013 20
Healthpoint Biotherapeutics - Discontinued Pipeline Products, 2013 21
Healthpoint Biotherapeutics, Deals Summary 28
Healthpoint Biotherapeutics Acquires Regranex Gel From Systagenix 29
Healthpoint Acquires Two Cell Based Technologies From Intercytex 31
Healthpoint Enters Into Agreement With Hydrofera 33
CareFusion Enters Into Licensing Agreement With Healthpoint 34
Smith and Nephew Completes Acquisition Of Healthpoint Biotherapeutics, Wound Care Company, For $782 Million 36



List of Figures

Healthpoint Biotherapeutics - Pipeline by Indication, 2013 7
Healthpoint Biotherapeutics - Pipeline by Stage of Development, 2013 8
Healthpoint Biotherapeutics - Monotherapy Products in Pipeline, 2013 9

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Protalix BioTherapeutics, Inc. (PLX) - Financial and Strategic SWOT Analysis Review

Protalix BioTherapeutics, Inc. (PLX) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary Protalix BioTherapeutics, Inc. (Protalix) is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company provides elelyso, a plant cell-expressed ...

Northwest Biotherapeutics, Inc. (NWBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Northwest Biotherapeutics, Inc. (NWBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • August 2016
  • by Global Data

Summary Northwest Biotherapeutics, Inc. (NW Bio) is a development stage biotechnology company. It discovers and develops immunotherapy products to treat cancer in an effective way without toxicities associated ...

Oxford BioTherapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Oxford BioTherapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • September 2016
  • by Global Data

Summary Oxford BioTherapeutics Ltd (Oxford BioTherapeutics) is a biotechnology company that focuses on the development antibody drug conjugates (ACDs) for the treatment of wide variety of cancers. The ...

Eleven Biotherapeutics Inc

November 2016 $ 87

Northwest Biotherapeutics, Inc.

November 2016 $ 87

Asterias Biotherapeutics Inc

November 2016 $ 87

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.